Neovasc Plans Next Steps After Thumbs Down From FDA Panel
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.
You may also be interested in...
Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.
The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.
What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?